Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AP-PA02

Other · Kills target cells, directed at Pseudomonas aeruginosa · developed by Armata Pharmaceuticals

Phase 2 Most advanced trial (none active)

ARMP Developer

1 Registered trials

What is AP-PA02?

AP-PA02 is a bacteriophage administered via inhalation. It is studied in non-cystic fibrosis bronchiectasis and lung infections caused by Pseudomonas aeruginosa.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Targets: Pseudomonas aeruginosa (antigen)
Mechanism: Kills target cells, directed at Pseudomonas aeruginosa
Therapy area: Infectious disease
Developer: Armata Pharmaceuticals, Inc. (ARMP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05616221	Phase 2	Non-cystic Fibrosis Bronchiectasis	Completed	ARMP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lung InfectionNon-cystic Fibrosis BronchiectasisPseudomonas Aeruginosa

More from Armata Pharmaceuticals

AB-PA01 N/A AB-SA01 Phase 1 AP-SA02 Phase 1/2 C16G2 Phase 2 C16G2 Rinse Phase 2 C16G2 Strip Phase 2

Sources

ClinicalTrials.gov NCT05616221

Updated Oct 11, 2026. Something wrong or missing? Report it on the ARMP page.

Follow ARMP, the company behind AP-PA02

See ARMP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARMP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z